Author

Paula Codó

Observed names: P. Codo, P. Codó, Paula Codo, Paula L. Codo, Paula L. Codó

Institution: CureVac (Germany)

Observed institutions: Fujita Health University, Jawaharlal Nehru Centre for Advanced Scientific Research, Chinese University of Hong Kong, German Cancer Research Center, University of Zurich, Karolinska Institutet, Acıbadem University, University Hospital Zurich, National Center for Tumor Diseases, Pitié-Salpêtrière Hospital, CureVac (Germany), Nationales Centrum für Tumorerkrankungen Dresden, German Cancer Research Center (DKFZ) Dresden

OpenAlex ID: A5047590296

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

2018 · Christoph Heining, Peter Horak, et al. · Cancer Discovery · 242

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer

2021 · Sebastian M. Dieter, Christine Siegl, et al. · Cell Reports · 96

MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape

2014 · Paula Codo, Michael Weller, et al. · Oncotarget · 95

Control of glioma cell migration and invasiveness by GDF-15

2016 · Paula Codó, Michael Weller, et al. · Oncotarget · 50

Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients

2014 · Patrick Roth, Andreas Keller, et al. · European Journal of Cancer · 36

A ribonucleotide reductase inhibitor with deoxyribonucleoside‐reversible cytotoxicity

2016 · Mikael Crona, Paula Codó, et al. · Molecular Oncology · 23

Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis

2018 · Prajakta Khalkar, Hani Abdulkadir Ali, et al. · Free Radical Biology and Medicine · 20

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma

2025 · Thomas Eigentler, Ioannis Thomas, et al. · Journal for ImmunoTherapy of Cancer · 11

786 Intratumorally administered CV8102 in patients with advanced solid tumors: preliminary results from ongoing expansion part in study 008

2022 · Thomas Eigentler, Igor Samoylenko, et al. · Journal for ImmunoTherapy of Cancer · 2

A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany)

2024 · Frank Kowalzik, Daniel Teschner, et al. · Vaccine X · 1

P02.04 * Microrna-mediated Down-regulation of Nkg2d Ligand Expression Reduces Glioma Cell Immunogenicity

2014 · P. Codo, M. Weller, et al. · Neuro-Oncology · 1

Omics and Prognstic Markers

2013 · K. Adachi, H. Sasaki, et al. · Neuro-Oncology · 1

784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion

2022 · Marina Gonzalez, Peter Wengenmayer, et al. · Journal for ImmunoTherapy of Cancer

473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in phase I clinical trial

2021 · Paula Codó, Thomas Eigentler, et al. · Journal for ImmunoTherapy of Cancer

Works count: 15

Citation count: 578

H-index: 8

I10-index: 8